Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04585646 · ClinicalTrials.gov registry record · NA
A Two-Week Crossover Dispensing Evaluation Of Orion Daily Wear Soft Contact Lens
A NA study, sponsored by CooperVision.
- Completed
- Registry status
- NA
- Development phase
- 64
- Enrollment target
NCT04585646: Completed NA study, sponsored by CooperVision.
NCT04585646 is a NA study that has completed, run by CooperVision. The registered enrollment target is 64 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04585646, a NA study, has completed, sponsored by CooperVision.
- COMPLETED
- Registry status
- NA
- Development phase
- 64 participants
- Enrollment target
Study Summary
The primary objective of the study is to evaluate the clinical performance of test lens (Orion) in comparison with control lens (Gemini) over a period of two weeks of wear.
Primary Outcome
Subjective Response for Vision Satisfaction assessed on 7-point Likert (Very satisfied, Satisfied, Somewhat satisfied, Neither Satisfied nor Dissatisfied, Somewhat Dissatisfied, Dissatisfied, Very Dissatisfied)
Interventions
- DEVICE Orion daily disposable contact lens
- DEVICE Gemini daily disposable contact lens
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2020-09-14 |
| Est. Completion | 2020-12-31 |
| Phase | NA |
What the finished NCT04585646 record still lists
NCT04585646 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 64 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 2 interventions - of which Orion daily disposable contact lens is the first listed.
NCT04585646 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04585646 about?
NCT04585646 is a clinical study titled "A Two-Week Crossover Dispensing Evaluation Of Orion Daily Wear Soft Contact Lens". The primary objective of the study is to evaluate the clinical performance of test lens (Orion) in comparison with control lens (Gemini) over a period of two weeks of wear.
What is the current status of trial NCT04585646?
This trial is currently completed. It is a NA study. The enrollment target is 64 participants. The study started on 2020-09-14. Estimated completion is 2020-12-31.
What interventions are being tested in trial NCT04585646?
The interventions under investigation include: Orion daily disposable contact lens (DEVICE), Gemini daily disposable contact lens (DEVICE).
Who is sponsoring clinical trial NCT04585646?
This trial is sponsored by CooperVision, which has 64 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04585646's enrollment target sits among peer trials
64 1147th of 2000 higher than 844 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01853631 · 64 participants · Phase 1
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
- NCT03739502 · 64 participants · Phase 2
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
- NCT03739814 · 64 participants · Phase 2
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- NCT03866408 · 64 participants · Early Phase 1
Insulin Regulation of Lipolysis and Lipolysis Proteins
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI